INCYTE CORPORATION Deferred Income Tax Expense (Benefit)
INCYTE CORPORATION (INCY) reported Deferred Income Tax Expense (Benefit) of $247.69 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-10
- INCYTE CORPORATION deferred income tax expense (benefit) for fiscal 2025 was $247.69M.
- INCYTE CORPORATION deferred income tax expense (benefit) for fiscal 2024 was -$85.55M.
- INCYTE CORPORATION deferred income tax expense (benefit) for fiscal 2023 was -$158.90M, a 378.32% decline from fiscal 2022.
- INCYTE CORPORATION deferred income tax expense (benefit) for fiscal 2022 was $57.09M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $247.69M 10-K · filed 2026-02-10 |
| 2024-12-31 | -$85.55M 10-K · filed 2026-02-10 |
| 2023-12-31 | -$158.90M 10-K · filed 2026-02-10 |
| 2022-12-31 | $57.09M 10-K · filed 2025-02-10 |
| 2021-12-31 | -$465.60M 10-K · filed 2024-02-13 |
| 2020-12-31 | -$350.00K 10-K · filed 2023-02-07 |
| 2019-12-31 | -$377.00K 10-K · filed 2022-02-08 |
| 2018-12-31 | -$459.00K 10-K · filed 2021-02-09 |
| 2017-12-31 | -$805.00K 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |